Glycylcyclines: Third-generation tetracycline antibiotics

Current Opinion in Pharmacology

Volumn 1, Issue 5, 2001, Pages 464-469

  Chopra, Ian ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CL 331002; TETRACYCLINE DERIVATIVE;

ANIMAL; ANTIBIOTIC RESISTANCE; CHEMISTRY; GENETICS; HUMAN; METHODOLOGY; PHARMACEUTICS; REVIEW;

ANIMAL; ANTIBIOTICS, TETRACYCLINE; HUMAN; TECHNOLOGY, PHARMACEUTICAL; TETRACYCLINE RESISTANCE; TETRACYCLINES;

EID: 0035487002     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00081-9     Document Type: Review

References (36)

1. Chopra I, Hodgson J, Metcalf B, Poste G: The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicrob Agents Chemother 1997, 41:497-503.
2. Cassell GH: Emergent antibiotic resistance: health risks and economic impact. FEMS Immunol Med Microbiol 1997, 18:271-274.
3. Cohen ML: Changing patterns of infectious disease. Nature 2000, 406:762-767. This review summarises recent demographic and epidemiological changes affecting infectious diseases, including bacterial infections.
4. Tenover FC, Biddle JW, Lancaster MV: Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001, 7:327-332.
5. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP: Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001, 357:1179. The authors report the emergence of enterococcal resistance to linezolid in the clinical setting. The emergence of resistance has been disappointingly rapid in view of the fact that linezolid represents a new antibiotic class (the oxazolidinones), only approved by the FDA in 2000.
6. Knowles DJC: New strategies for antibacterial drug design. Trends Microbiol 1997, 5:379-383.
7. Testa RT, Petersen PJ, Jacobus NL, Sum PE, Lee VJ, Tally FP: In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother 1993, 37:2270-2277.
8. Sum PE, Lee VJ, Testa RT, Hlavka JJ, Ellestad GA, Bloom JD, Gluzman Y, Tally FP: Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J Med Chem 1994, 37:184-188.
9. Barden TC, Buckwalter BL, Testa RT, Petersen PJ, Lee VJ: Glycylcyclines 3.9-aminodoxycyclinecarboxamides. J Med Chem 1994, 37:3205-3211.
10. Chopra I, Roberts M: Tetracycline antibiotics: mode of action, applications, molecular biology and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001, 65:232-260. A recent comprehensive review discussing microbiological, molecular and medical aspects of tetracyclines and the discovery and development of the glycylcyclines
11. Johnson AP: GAR-936. Curr Opin Anti-infect Invest Drugs 2000, 2:164-170.
12. Ross JI, Eady EA, Cove JH, Cunliffe WJ: 16S rRNA mutation associated with tetracycline resistance in a Gram-positive bacterium. Antimicrob Agents Chemother 1998, 42:1702-1705.
13. Rasmussen BA, Gluzman Y, Tally FP: Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents Chemother 1994, 38:1658-1660.
14. Sum PE, Petersen P: Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 1999, 9:1459-1462.
15. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT: In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999, 43:738-744.
16. Nord CE, Lindmark A, Persson I: In vitro activity of DMG-Mino and DMG-DM Dot, two new glycylcyclines, against anaerobic bacteria. Eur J Clin Microbiol Infect Dis 1993, 12:784-786.
17. Eliopoulos GM, Wennersten CB, Cole G, Moellering RC: In vitro activities of two glycylcyclines against Gram-positive bacteria. Antimicrob Agents Chemother 1994, 38:534-541.
18. Goldstein FW, Kitzis MD, Acar JF: N,N-dimethylglycyl-amido derivative of minocycline and 6-demethyl-6-deoxytetracycline, two new glycylcyclines highly effective against tetracycline-resistant Gram-positive cocci. Antimicrob Agents Chemother 1994, 38:2218-2220.
19. Kenny GE, Cartwright FD: Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines. Antimicrob Agents Chemother 1994, 38:2628-2632.
20. Wexler HM, Molitoris E, Finegold SM: In vitro activities of two new glycylcyclines, N,N-dimethylglycylamido derivatives of minocycline and 6-demethyl-6-deoxytetracycline, against 339 strains of anaerobic bacteria. Antimicrob Agents Chemother 1994, 38:2513-2515
21. Wise R, Andrews JM: In vitro activities of two glycylcyclines. Antimicrob Agents Chemother 1994, 38:1096-1102.
22. Fraise AP, Brenwald N, Andrews JM, Wise R: In vitro activity of two glycylcyclines against enterococci resistant to other agents. J Antimicrob Chemother 1995, 35:877-881.
23. Weiss WJ, Jacobus NV, Petersen PJ, Testa RT: Susceptibility of enterococci, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae to the glycylcyclines. J Antimicrob Chemother 1995, 36:225-230.
24. Whittington WL, Roberts MC, Hale J, Holmes KK: Susceptibilities of Neisseria gonorrhoeae to the glycylcyclines. Antimicrob Agents Chemother 1995, 39:1864-1865.
25. Brown BA, Wallace RJ, Onyi G: Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria. Antimicrob Agents Chemother 1996, 40:874-878.
26. Hamilton-Miller JMT, Shah S: Activity of glycylcyclines CL 329998 and CL 331002 against minocycline-resistant and other strains of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1996, 37:1171-1175.
27. Shonekan D, Handwerger S, Mildvan D: Comparative in vitro activities of RP59500 (quinupristin/ dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. J Antimicrob Chemother 1997, 39:405-409.
28. Boucher HW, Wennersten CB, Eliopoulos GM: In vitro activities of the glycylcycline GAR-936 against Gram-positive bacteria. Antimicrob Agents Chemother 2000, 44:2225-2229. This paper presents the results of in vitro susceptibility testing with GAR-936 (the candidate clinical glycylcycline) against a large collection of Gram-positive clinical isolates. The data generally demonstrate the superior activity of GAR-936 compared with earlier tetracyclines.
29. Gales AC, Jones RN: Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microb Infect Dis 2000, 36:19-36. This paper presents the results of in vitro susceptibility testing with GAR-936 against a large collection of Gram-positive and Gram-negative clinical isolates. The data generally demonstrate the superior activity of GAR-936 compared with earlier tetracyclines.
30. van Ogtrop ML, Andes D, Stamstad TJ, Conklin B, Weiss WJ, Craig WA, Vesga O: In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 2000, 44:943-949. This paper reports promising pharmacodynamic data for GAR-936 in a variety of murine infection models. It also reports pharmacokinetic data in mice and predicts a possible dosing regimen for GAR-936 for therapeutic use in man.
31. Projan SJ: Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000, 20:219S-223S.
32. Muralidharan G, Getsy J, Mayer P, Paty I, Micalizzi M, Speth J, Wester B, Mojaverian P: Pharmacokinetics (PK), safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): 1999 Sept 26-29; San Francisco. Washington DC: American Society for Microbiology; 1999:303.
33. Tuckman M, Petersen PJ, Projan SJ: Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microbiol Drug Res 2000, 6:277-282. This paper describes the molecular basis of resistance to early members of the glycylcyclines arising in Gram-negative tet efflux pumps. It also addresses the potential for resistance to GAR-936 arising by further mutation in existing tetracycline efflux pumps.
34. Guay GG, Tuckman M, Rothstein DM: Mutations in the tetA(B) gene that cause a change in substrate specificity of the tetracycline efflux pump. Antimicrob Agents Chemother 1994, 38:857-860.
35. Finch RG: Tetracyclines. In Antibiotic and Chemotherapy, edn 7. Edited by O'Grady F, Lambert HP, Finch RG, Greenwood D. New York: Churchill Livingstone; 199:469-484.
36. Chopra I: Antibiotics. The Encyclopedia of Life Sciences (in press). URL: www.els.net